HC Wainwright Reiterates “Buy” Rating for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $40.00 price objective on the biotechnology company’s stock.

Other equities research analysts also recently issued research reports about the company. StockNews.com upgraded Capricor Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 24th. Cantor Fitzgerald initiated coverage on Capricor Therapeutics in a research report on Friday, January 5th. They set an “overweight” rating and a $8.00 price objective for the company.

Capricor Therapeutics Price Performance

CAPR opened at $5.41 on Thursday. The company has a market capitalization of $170.42 million, a price-to-earnings ratio of -6.14 and a beta of 3.99. Capricor Therapeutics has a 1-year low of $2.68 and a 1-year high of $8.22. The business has a 50 day moving average price of $5.61 and a two-hundred day moving average price of $4.35.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Thursday, February 29th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.21. The firm had revenue of $12.09 million during the quarter, compared to the consensus estimate of $5.80 million. Capricor Therapeutics had a negative return on equity of 299.67% and a negative net margin of 88.52%. Equities analysts expect that Capricor Therapeutics will post -0.83 EPS for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

An institutional investor recently bought a new position in Capricor Therapeutics stock. Citigroup Inc. bought a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 61,591 shares of the biotechnology company’s stock, valued at approximately $211,000. Citigroup Inc. owned approximately 0.20% of Capricor Therapeutics as of its most recent SEC filing. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.